Hamdy E A Ali1, Ahmed A Emam2, Ahmed A Zeeneldin3, Reham Srour2, Reda Tabashy4, Eman D El-Desouky5, Zakaria Y Abd Elmageed6, Abdel-Hady A Abdel-Wahab7. 1. Department of Pharmaceutical Sciences, Rangel College of Pharmacy, Texas A&M Health Sciences Center, College Station, TX, USA; Department of Radiobiological Applications, Nuclear Research Center, Atomic Energy Authority, Cairo, Egypt. 2. Department of Cancer Biology, National Cancer Institute, Cairo University, Cairo, Egypt. 3. Medical Oncology Department, National Cancer Institute, Cairo University, Kasr Al-Eini Street, Fom El Khalig, Cairo, Egypt. 4. Department of Radiodiagnosis, National Cancer Institute, Cairo University, Cairo, Egypt. 5. Epidemiology and Biostatistics Department, National Cancer Institute, Cairo, Egypt. 6. Department of Pharmaceutical Sciences, Rangel College of Pharmacy, Texas A&M Health Sciences Center, College Station, TX, USA. Electronic address: elmageed@tamhsc.edu. 7. Department of Cancer Biology, National Cancer Institute, Cairo University, Cairo, Egypt. Electronic address: abdelhady.abdelwahab@nci.cu.edu.eg.
Abstract
BACKGROUND: A number of hepatocellular carcinoma (HCC) patients have developed resistance against transcatheter arterial chemoembolization (TACE) treatment. In this study, we aimed to develop a panel of microRNAs (miRs) biomarkers to predict clinical outcomes in HCC patients after TACE treatment. METHODS: The expression level of twenty miRs was evaluated in FFPE tissues collected from 33 HCC patients. We selected four differentially expressed miRs in TACE-responders versus non-responders and re-assessed their expression in 51 serum samples. The expressions of miRs associated with overall survival (OS), progression-free survival (PFS), and treatment outcomes were investigated. The diagnostic accuracy of these miRs in predicting patients' response to TACE was also evaluated. RESULTS: The baseline of miR-106b, miR-107 and miR-133b was significantly elevated (p < .001) in sera of TACE-responders while miR-26a was elevated (p < .001) in non-responders. miR-26a and miR-133b recorded the highest diagnostic performance as individual classifiers in response to TACE (AUC = 1.0 and 100% sensitivity and specificity). Intriguingly, miR-133b distinguished complete responders from partial responders and non-responders (AUC ≥ 0.90). The PFS was improved (p < .05) in the high expression group of miR-31, miR-200b, miR-133b and miR-181a over their low expression group. CONCLUSION: Circulating miR-133b, miR-26a, miR-107 and miR-106 in serum are potential candidates to be utilized as prognostic biomarkers for predication of TACE treatment outcomes in HCC patients.
BACKGROUND: A number of hepatocellular carcinoma (HCC) patients have developed resistance against transcatheter arterial chemoembolization (TACE) treatment. In this study, we aimed to develop a panel of microRNAs (miRs) biomarkers to predict clinical outcomes in HCCpatients after TACE treatment. METHODS: The expression level of twenty miRs was evaluated in FFPE tissues collected from 33 HCCpatients. We selected four differentially expressed miRs in TACE-responders versus non-responders and re-assessed their expression in 51 serum samples. The expressions of miRs associated with overall survival (OS), progression-free survival (PFS), and treatment outcomes were investigated. The diagnostic accuracy of these miRs in predicting patients' response to TACE was also evaluated. RESULTS: The baseline of miR-106b, miR-107 and miR-133b was significantly elevated (p < .001) in sera of TACE-responders while miR-26a was elevated (p < .001) in non-responders. miR-26a and miR-133b recorded the highest diagnostic performance as individual classifiers in response to TACE (AUC = 1.0 and 100% sensitivity and specificity). Intriguingly, miR-133b distinguished complete responders from partial responders and non-responders (AUC ≥ 0.90). The PFS was improved (p < .05) in the high expression group of miR-31, miR-200b, miR-133b and miR-181a over their low expression group. CONCLUSION: Circulating miR-133b, miR-26a, miR-107 and miR-106 in serum are potential candidates to be utilized as prognostic biomarkers for predication of TACE treatment outcomes in HCCpatients.
Authors: Andreas Karakatsanis; Ioannis Papaconstantinou; Maria Gazouli; Anna Lyberopoulou; George Polymeneas; Dionysios Voros Journal: Mol Carcinog Date: 2011-12-27 Impact factor: 4.784
Authors: Ghassan K Abou-Alfa; Philip Johnson; Jennifer J Knox; Marinela Capanu; Irina Davidenko; Juan Lacava; Thomas Leung; Bolorsukh Gansukh; Leonard B Saltz Journal: JAMA Date: 2010-11-17 Impact factor: 56.272
Authors: C Kuroda; M Sakurai; M Monden; T Marukawa; T Hosoki; K Tokunaga; K Wakasa; J Okamura; T Kozuka Journal: Cancer Date: 1991-01-01 Impact factor: 6.860
Authors: Antoinette S Gomes; Michael H Rosove; Peter J Rosen; Rafael G Amado; James W Sayre; Phillip A Monteleone; Ronald W Busuttil Journal: AJR Am J Roentgenol Date: 2009-12 Impact factor: 3.959
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Sven H Loosen; Mirco Castoldi; Markus S Jördens; Sanchary Roy; Mihael Vucur; Jennis Kandler; Linda Hammerich; Raphael Mohr; Frank Tacke; Tom F Ulmer; Ulf P Neumann; Tom Luedde; Christoph Roderburg Journal: PLoS One Date: 2021-03-12 Impact factor: 3.240
Authors: Alessandro Marco Bozzato; Paola Martingano; Roberta Antea Pozzi Mucelli; Marco Francesco Maria Cavallaro; Matteo Cesarotto; Cristina Marcello; Claudio Tiribelli; Devis Pascut; Riccardo Pizzolato; Fabio Pozzi Mucelli; Mauro Giuffrè; Lory Saveria Crocè; Maria Assunta Cova Journal: Diagnostics (Basel) Date: 2022-02-01